日前,美国食品和药品管理局批准了Cook医疗公司的紫杉醇-洗脱外周动脉支架Zilver PTX用于治疗股浅动脉性疾病,这是第一个获FDA批准的药物洗脱性外周动脉支架。根据Cook公司一项为期2年涉及500名患者的试验,该洗脱支架的治疗效果均优于针对截肢终点、 Recently, the U.S. Food and Drug Administration approved Cook’s medical-sponsored paclitaxel-eluting peripheral arterial stent, Zilver PTX, for the treatment of superficial femoral artery disease, the first FDA-approved drug-eluting peripheral arterial stent. According to Cook’s two-year trial involving 500 patients, the eluting stents are superior to those for amputation,